Early-onset colorectal cancer incidence in Norway: a national registry-based study (1993-2022) analyzing subsite and morphology trends
Exploring Early Kinetic Profiles of CEA, ctDNA and cfDNA in Patients With RAS-/BRAF-Mutated Metastatic Colorectal Cancer.
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe.
IMPRESS-Norway: improving public cancer care by implementing precision medicine in Norway; inclusion rates and preliminary results.
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.
Supplementary Methods S1 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S3 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Data from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S10 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S2 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S9 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S11 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S12 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S4 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S7 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S1 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S13 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Figure S1 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S8 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Figure S2 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S5 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Supplementary Table S6 from Evaluating Debio 1347 in Patients with <i>FGFR</i> Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial
Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE‐158 study
Supplementary Data from Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Data from Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Supplementary Data from Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Supplementary Data from Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Data from Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Supplementary Data from Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity